Introduction of ordinary series A and B bearer shares to be traded on the Main Market of the Warsaw Stock Exchange
10.04.2026
See also
KNF has approved the Syn2bio prospectus. The debut on the WSE is planned for April
- Corporate news
- Investor relations
Synektik one step closer to planned division
- Corporate news
- Investor relations
Synektik shareholders have unanimously approved the division of the company and spinoff of the cardiotracer project to Syn2bio
- Corporate news
- Investor relations